{
    "root": "26654311-614c-43b0-a865-916e5afcf6aa",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate",
    "value": "20250317",
    "ingredients": [
        {
            "name": "AMPHETAMINE SULFATE",
            "code": "6DPV8NK46S"
        },
        {
            "name": "AMPHETAMINE ASPARTATE MONOHYDRATE",
            "code": "O1ZPV620O4"
        },
        {
            "name": "DEXTROAMPHETAMINE SULFATE",
            "code": "JJ768O327N"
        },
        {
            "name": "DEXTROAMPHETAMINE SACCHARATE",
            "code": "G83415V073"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "GLYCERYL MONOSTEARATE",
            "code": "230OU9XXE4"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C GREEN NO. 3",
            "code": "3P3ONR6O1S"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "dextroamphetamine saccharate , amphetamine aspartate monohydrate , dextroamphetamine sulfate , amphetamine sulfate extended-release capsules , cns stimulant , indicated treatment attention deficit hyperactivity disorder ( adhd ) . ( 1 ) \u2022 children ( ages 6-12 ) : efficacy established one 3-week outpatient , controlled trial one analogue classroom , controlled trial children adhd . ( 14 ) \u2022 adolescents ( ages 13-17 ) : efficacy established one 4-week controlled trial adolescents adhd . ( 14 ) \u2022 adults : efficacy established one 4-week controlled trial adults adhd . ( 14 )",
    "contraindications": "\u2022 pediatric patients ( ages 6-17 ) : 10 mg daily morning . maximum dose children 6-12 years age 30 mg daily . ( 2.2 , 2.3 , 2.4 ) \u2022 adults : 20 mg daily morning . ( 2.5 ) \u2022 pediatric patients ( ages 6-17 ) severe renal impairment : 5 mg daily morning . maximum dose children 6- 12 years age severe renal impairment 20 mg daily . ( 2.6 , 8.6 ) \u2022 adults severe renal impairment : 15 mg daily morning . ( 2.6 , 8.6 ) \u2022 patients esrd : recommended . ( 2.6 , 8.6 )",
    "warningsAndPrecautions": "dextroamphetamine saccharate , amphetamine aspartate monohydrate , dextroamphetamine sulfate , amphetamine sulfate extended-release capsules 10 mg hard gelatin capsules , green opaque cap body , printed \u201c amg \u201d cap \u201c 278 \u201d body , supplied follows : bottles 100 ndc 63629-1973-1 dispense tight , light-resistant container defined usp . store room temperature , 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) . [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "dextroamphetamine saccharate , amphetamine aspartate monohydrate , dextroamphetamine sulfate , amphetamine sulfate extended-release capsule contraindicated patients following conditions : \u2022advanced arteriosclerosis \u2022symptomatic cardiovascular disease \u2022moderate severe hypertension \u2022hyperthyroidism \u2022in patients known hypersensitive amphetamine , components dextroamphetamine saccharate , amphetamine aspartate monohydrate , dextroamphetamine sulfate , amphetamine sulfate extended-release capsules . hypersensitivity angioedema anaphylactic reported patients treated amphetamine products [ ( 6.2 ) ] \u2022glaucoma \u2022agitated states \u2022history abuse \u2022patients taking monoamine oxidase inhibitors ( maois ) , within 14 days stopping maois ( including maois linezolid intravenous methylene blue ) , increased risk hypertensive crisis [ ( 5.6 ) ( 7.1 ) ]",
    "indications_original": "Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, a CNS stimulant, are indicated for the treatment of attention deficit hyperactivity disorder (ADHD). ( 1 ) \u2022 Children (ages 6-12): Efficacy was established in one 3-week outpatient, controlled trial and one analogue classroom, controlled trial in children with ADHD. ( 14 ) \u2022 Adolescents (ages 13-17): Efficacy was established in one 4-week controlled trial in adolescents with ADHD. ( 14 ) \u2022 Adults: Efficacy was established in one 4-week controlled trial in adults with ADHD. ( 14 )",
    "contraindications_original": "\u2022 Pediatric patients (ages 6-17): 10 mg once daily in the morning. Maximum dose for children 6-12 years of age is 30 mg once daily. ( 2.2 , 2.3 , 2.4 ) \u2022 Adults: 20 mg once daily in the morning. ( 2.5 ) \u2022 Pediatric patients (ages 6-17) with severe renal impairment: 5 mg once daily in the morning. Maximum dose for children 6- 12 years of age with severe renal impairment is 20 mg once daily. ( 2.6 , 8.6 ) \u2022 Adults with severe renal impairment: 15 mg once daily in the morning. ( 2.6 , 8.6 ) \u2022 Patients with ESRD: not recommended. ( 2.6 , 8.6 )",
    "warningsAndPrecautions_original": "Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules 10 mg are hard gelatin capsules, green opaque cap and body, printed \u201cAMG\u201d on cap and \u201c278\u201d on body, which are supplied as follows:\n                  \n                     Bottles of 100 NDC\u00a063629-1973-1\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP.\n                  Store at room temperature, 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F). [see USP CONTROLLED ROOM TEMPERATURE].\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule administration is contraindicated in patients with the following conditions:\n                  \n                     \n                        \u2022Advanced arteriosclerosis\n                     \n                        \u2022Symptomatic cardiovascular disease \n                     \n                        \u2022Moderate to severe hypertension \n                     \n                        \u2022Hyperthyroidism \n                     \n                        \u2022In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions (6.2)]\n                     \n                     \n                        \u2022Glaucoma \n                     \n                        \u2022Agitated states \n                     \n                        \u2022History of drug abuse \n                     \n                        \u2022Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.6) and Drug Interactions (7.1)]"
}